Peapack Gladstone Financial Corp Has $2.52 Million Holdings in Thermo Fisher Scientific (TMO)

Peapack Gladstone Financial Corp grew its position in shares of Thermo Fisher Scientific (NYSE:TMO) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,214 shares of the medical research company’s stock after purchasing an additional 332 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Thermo Fisher Scientific were worth $2,522,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Providence Capital Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 4.1% in the 1st quarter. Providence Capital Advisors LLC now owns 8,647 shares of the medical research company’s stock valued at $1,785,000 after acquiring an additional 338 shares in the last quarter. Toronto Dominion Bank increased its stake in shares of Thermo Fisher Scientific by 21.9% in the 1st quarter. Toronto Dominion Bank now owns 271,720 shares of the medical research company’s stock valued at $56,088,000 after acquiring an additional 48,878 shares in the last quarter. Lido Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 11.3% in the 1st quarter. Lido Advisors LLC now owns 4,954 shares of the medical research company’s stock valued at $1,022,000 after acquiring an additional 501 shares in the last quarter. Advisors Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 6.2% in the 1st quarter. Advisors Capital Management LLC now owns 58,797 shares of the medical research company’s stock valued at $12,139,000 after acquiring an additional 3,430 shares in the last quarter. Finally, Alleghany Corp DE bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at $49,551,000. Hedge funds and other institutional investors own 85.86% of the company’s stock.

Shares of TMO stock opened at $213.65 on Friday. The firm has a market cap of $85.96 billion, a price-to-earnings ratio of 21.58, a price-to-earnings-growth ratio of 1.57 and a beta of 1.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 0.95. Thermo Fisher Scientific has a 12 month low of $170.07 and a 12 month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.08. The business had revenue of $5.85 billion during the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. Thermo Fisher Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.08 EPS. analysts forecast that Thermo Fisher Scientific will post 10.9 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.17 per share. The ex-dividend date is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.17%.

Several analysts have recently weighed in on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research note on Monday, April 30th. Leerink Swann reiterated an “outperform” rating and issued a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Morgan Stanley lowered their price objective on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating for the company in a research note on Wednesday, April 11th. Bank of America lifted their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Finally, ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $224.38.

In other Thermo Fisher Scientific news, Director C Martin Harris sold 206 shares of Thermo Fisher Scientific stock in a transaction on Friday, May 18th. The shares were sold at an average price of $214.43, for a total transaction of $44,172.58. Following the transaction, the director now directly owns 5,106 shares of the company’s stock, valued at approximately $1,094,879.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now directly owns 334,622 shares in the company, valued at $70,324,159.52. The disclosure for this sale can be found here. Insiders have sold a total of 42,706 shares of company stock valued at $8,962,073 in the last 90 days. 0.49% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply